Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
How has the blood based biomarkers market size changed in recent years, and what is the outlook ahead?
The blood based biomarkers market size has grown rapidly in recent years. It will grow from $23.13 billion in 2024 to $26.06 billion in 2025 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to rising cancer incidence globally, growing adoption of personalized medicine, increased funding in biomarker research, expansion of clinical trials involving biomarkers, and a rise in companion diagnostics approvals.
The blood based biomarkers market size is expected to see rapid growth in the next few years. It will grow to $41.55 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to the expansion of AI and machine learning in biomarker analysis, increased demand for early disease detection, the growth of telemedicine and remote diagnostics, the rising prevalence of chronic diseases, and increased consumer health awareness. Major trends in the forecast period include AI-driven biomarker discovery, liquid biopsy advancements, multi-omics integration, point-of-care (POC) testing devices, and next-generation sequencing (NGS) innovations.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24176&type=smp
What are the top economic and technological drivers pushing blood based biomarkers market growth?
The growing cases of cardiovascular diseases are expected to propel the growth of the blood-based biomarkers market going forward. Cardiovascular diseases refer to a group of disorders affecting the heart and blood vessels, including conditions like coronary artery disease, heart failure, and stroke. The rise in cardiovascular diseases is largely due to increasing risk factors such as poor diet and rising obesity rates. Blood-based biomarkers help diagnose and monitor cardiovascular diseases by providing insights into disease progression, risk assessment, and treatment response through measurable substances in the blood. For instance, in September 2024, according to the National Center for Biotechnology Information, a US-based government agency reported a global health research initiative. Projections indicated a 90% rise in cardiovascular disease prevalence between 2025 and 2050, with expected cardiovascular deaths reaching 35.6 million by 2050. Therefore, the growing cases of cardiovascular diseases are driving the growth of blood-based biomarkers.
How is the blood based biomarkers market segmented by product, application, and end-user?
The blood based biomarkers market covered in this report is segmented –
1) By Type: Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-Based Biomarkers, Epigenetic Biomarkers
2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Immunoassays, Mass Spectrometry, Other Technologies
3) By Application: Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Other Applications
4) By End Users: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutes, Other End Users
Subsegments:
1) By Genetic Biomarkers: Deoxyribonucleic Acid (DNA) Mutations, Ribonucleic Acid (RNA) Expression Profiles, Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Fusions
2) By Protein Biomarkers: Enzymes, Hormones, Cytokines, Tumor Markers, Acute Phase Proteins
3) By Metabolic Biomarkers: Lipid Profiles, Amino Acid Levels, Glucose And Lactate Levels, Organic Acids, Metabolite Panels
4) By Cell-Based Biomarkers: Circulating Tumor Cells (CTCs), Immune Cell Profiling, Stem Cells, Platelets, Endothelial Cells
5) By Epigenetic Biomarkers: Deoxyribonucleic Acid (DNA) Methylation Patterns, Histone Modifications, Non-Coding Ribonucleic Acid (RNA), Chromatin Accessibility, Epigenetic Enzyme Activity
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/blood-based-biomarkers-global-market-report
What evolving trends are creating new opportunities in the blood based biomarkers market?
Major companies operating in the blood-based biomarkers market are focusing on technological advancements such as high-accuracy blood biomarker tests to aid physician diagnosis of Alzheimer’s disease. A high-accuracy blood biomarker test is a diagnostic tool that uses specific biomarkers in the blood to detect diseases or monitor health conditions with a high level of precision and reliability. For instance, in October 2023, Quanterix, a US-based life sciences company, launched a high-accuracy blood biomarker test called LucentAD p-Tau 217 to aid physicians in diagnosing Alzheimer’s disease (AD) in adults with cognitive impairment. This test measures phosphorylated tau protein at threonine 217 (p-Tau 217), a biomarker strongly associated with AD pathology, particularly amyloid buildup in the brain. The LucentAD p-Tau 217 test achieves over 90% accuracy, meeting stringent diagnostic criteria, and is intended to be used alongside other diagnostic tools rather than as a standalone test.
Which leading companies are dominating the blood based biomarkers market landscape?
Major companies operating in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG
Which geographic areas are expected to offer the highest growth opportunities in theblood based biomarkers market?
North America was the largest region in the blood-based biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blood based biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Blood Based Biomarkers Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24176&type=smp
Need Customized Data On Blood Based Biomarkers Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24176&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
